Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Mar 30, 2022 · 10-K · 89 days after period end · 0001493152-22-008156
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | — |
| Net Income | -$3.18M | -$9.73M | -$774.44K | -$609.35K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 30, 2022 · 89 d after period end
